| Literature DB >> 20920239 |
Gudrun Rohde1, Glenn Haugeberg, Anne Marit Mengshoel, Torbjorn Moum, Astrid K Wahl.
Abstract
BACKGROUND: The long-term effect of hip fracture on health-related quality of life (HRQOL) and global quality of life (GQOL) has not been thoroughly studied in prospective case-control studies. AIMS: a) to explore whether patients with low-energy hip fracture regain their pre-fracture levels in HRQOL and GQOL compared with changes in age- and sex-matched controls over a two year period; b) to identify predictors of changes in HRQOL and GQOL after two years.Entities:
Mesh:
Year: 2010 PMID: 20920239 PMCID: PMC2954991 DOI: 10.1186/1471-2474-11-226
Source DB: PubMed Journal: BMC Musculoskelet Disord ISSN: 1471-2474 Impact factor: 2.362
Figure 1Flow chart of the patients with hip fractures at baseline and at one- and two-year follow-up.
Demographics and clinical characteristics in patients with hip fractures (n = 61) and controls (n = 61) at baseline.
| Patients with hip fractures | Controls | ||||
|---|---|---|---|---|---|
| Mean ( | n (%) | Mean ( | n (%) | ||
| Age (years) | 73.7 (9.5) | 72.6 (8.2) | 0.502 | ||
| (range 50-90 years) | |||||
| Females | 46 (75) | 46 (75) | 1.000 | ||
| Current height (cm) | 167.8 (8.7) | 166.8 (7.9) | 0.513 | ||
| Current weight (kg) | 66.4 (12.2) | 74.7 (12.5) | |||
| BMI (kg/m2) | 23.6 (3.7) | 26.8 (3.7) | |||
| Education | 0.525 | ||||
| < 10 years | 26 (46) | 22 (37) | |||
| 11-13 years | 18 (32) | 21 (35) | |||
| > 13 years | 12 (21) | 17 (28) | |||
| Cohabiting | 26 (44) | 38 (62) | |||
| Regular exercise** | 36 (59) | 47 (77) | |||
| Current smoker | 16 (36) | 6 (10) | |||
| Current calcium and/or vitamin D treatment | 12 (20) | 18 (30) | 0.207 | ||
| Current ART | 9 (15) | 10 (16) | 0.803 | ||
| Current glucocorticoid treatment | 9 (16) | 3 (5) | 0.083 | ||
| Previous fractures | 28 (46) | 29 (48) | 0.362 | ||
| Mother fracture | 18 (30) | 18 (30) | 0.930 | ||
| ≥ one fall in the previous year | 27 (47) | 19 (37) | 0.289 | ||
| Osteoporosis *** | 35 (58) | 12 (20) | |||
| Osteopenia | 21 (34) | 29 (48) | |||
| Normal BMD | 5 (8) | 19 (32) | |||
| Heart diseases | 28 (48) | 30 (49) | 0.856 | ||
| Pulmonary diseases | 10 (16) | 5 (8) | 0.168 | ||
| Neurological diseases | 8 (13) | 3 (5) | 0.114 | ||
| Endocrine disorders | 5 (8) | 4 (7) | 0.729 | ||
| Gastrointestinal disorders | 6 (10) | 11 (18) | 0.191 | ||
| Urogenital disorders | 5 (8) | 2 (3) | 0.243 | ||
| Inflammatory joint/connective tissue disorders | 16 (26) | 13 (21) | 0.523 | ||
| Cancer | 8 (13) | 6 (10) | 0.570 | ||
| Mental disorders | 3 (5) | 2 (3) | 0.648 | ||
| Co-morbidities | 1.2 (1.1) | 1.5 (0.9) | 0.218 | ||
Continuous variables are presented as mean (SD) and group variables as numbers (%).
* Chi-square when comparing categorical data. Independent t tests with continuous variables. Bold p-values indicate significant differences between the groups. ** Exercise more than 30 minutes three times a week.
*** Osteoporosis at total hip and/or spine L2-L4.
**** Mean (SD) score of diseases including: heart diseases, pulmonary diseases, neurological disorders, urogenital disorders, gastrointestinal disorders, endocrine disorders, inflammatory joint disorders and connective tissue disorders, cancer and mental disorders.
BMI, body mass index; ART, antiresorptive treatment (specific osteoporosis treatment comprising biphosphonates, or selective oestrogen-receptor modulators).
Figure 2HRQOL and GQOL mean scores (95% confidence intervals) at baseline, and at one- and two-year follow-up in patients with hip fractures (n = 61) and controls (n = 61).
Figure 3Standard difference scores (s-scores) of HRQOL and GQOL at one- and two-year follow-up, compared with baseline for patients with hip fracture (n = 61) and controls (n = 61) with valid HRQOL and GQOL change-scores.
Predictors of change in HRQOL (delta PCS and delta MCS) and GQOL (delta QOLS) in patients with hip fractures (n = 61) and controls (n = 61).
| PCS | MCS | QOLS | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Age* | -1.0 | (-1.9, -0.2) | 0.05 | (-1.1, 1.2) | 0.926 | -0.4 | (-1.7, 0.9) | 0.529 | |
| Male | -0.5 | (-3.8, 2.9) | 0.783 | -2.4 | (-7.0, 2.2) | 0.310 | -1.4 | (-6.5, 3.7) | 0.590 |
| Female | Ref | Ref | Ref | ||||||
| Living alone | -2.9 | (-5.8, 0.0) | 0.050 | 3.5 | (-0.6, 7.5) | 0.093 | -0.1 | (-4.6, 4.4) | 0.968 |
| Cohabiting | Ref | Ref | Ref | ||||||
| Hip patients | -5.8 | (-8.7, -2.8) | -3.8 | (-7.9, 0.3) | 0.071 | -1.7 | (-6.1, 2.7) | 0.447 | |
| Controls | Ref | Ref | Ref | ||||||
| Osteopenia** | -0.8 | (-4.3, 2.8) | 0.671 | -0.5 | (-5.5, 4.5) | 0.837 | -3.2 | (-8.8, 2.4) | 0.265 |
| Osteoporosis** | 0.2 | (-3.9, 4.3) | 0.918 | -2.1 | (-7.9, 3.6) | 0.461 | 1.4 | (-4.7, 7.6) | 0.649 |
| Normal BMD | Ref | Ref | Ref | ||||||
| Co-morbidity | 0.0 | (-1.4, 1.4) | 0.999 | -2.2 | (-4.1, -0.2) | -0.3 | (-2.6, 2.0) | 0.783 | |
| PCS incl. | -0.3 | (-0.5, -0.2) | |||||||
| MCS incl. | -0.5 | (-0.8, -0.3) | |||||||
| QOLS incl. | -0.2 | (-0.5, 0.0) | |||||||
| 26.7% | 21.5% | 2.3% | |||||||
Adjusted unstandardized regression coefficients, 95% CI, and p values.
p-values marked with bold indicate statistically significance. The demographic and clinical variables in column one are used in all three
models, in addition PCS at inclusion is used in model one, MCS at inclusion in model two and QOLS at inclusion in model three
* Age in five-year groups.
** Osteopenia/osteoporosis at total hip and/or spine L2-L4.
BMD, bone mineral density; PCS, SF-36 physical component summary scale; MCS, SF-36 mental component summary scale
(range 0-100, where 100 = high HRQOL); QOLS, Quality of Life Scale (16-112, where 112 = high GQOL).